Prevention and Reversal of Diabetic Nephropathy in db/db Mice Treated with Alagebrium (ALT-711)
- 1 December 2006
- journal article
- research article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 26 (5), 430-436
- https://doi.org/10.1159/000095786
Abstract
Background: Alagebrium (ALT-711) has been shown to improve renal dysfunction in animal models of diabetes. Methods: To test its effects in diabetic nephropathy (DN), ALT-711 was administered (1 mg/kg daily i.p.) to 9-week-old female db/db mice (n = 15, group A1) for 3 weeks and to 3-month-old (n = 15, group A2), 7-month-old (n = 7, group A3), and 12-month-old (n = 5, group A4) female db/db mice for 12 weeks, while a similar number of diabetic and nondiabetic mice were used as controls. The ΕN-carboxymethyllysine (CML) levels in serum, urine, skin, and kidney tissue were measured by enzyme-linked immunosorbent assay. The renal morphometric parameters were assessed by electron and light microscopy. Results: By the 3rd week of treatment, the serum CML level decreased by 41%, and the urinary CML concentration increased by 138% from baseline, while the urinary albumin/creatinine ratio was lower (p < 0.05) in diabetic and nondiabetic group A1 mice. After 3 months of treatment, serum, skin, and kidney CML levels and urinary albumin/creatinine ratio were lower (p < 0.05) and the urinary CML levels higher (p < 0.05) in treated group A2, A3, and A4 animals compared with groups which received phosphate-buffered saline, with a similar pattern observed in nondiabetic mice. The renal morphological parameters characteristic of DN decreased in treated compared with untreated mice. Conclusion: Alagebrium may prevent, delay, and/or reverse established DN in db/db mice by reducing the systemic advanced glycation end product pools and facilitating the urinary excretion of advanced glycation end products.Keywords
This publication has 22 references indexed in Scilit:
- AGEs activate mesangial TGF-β–Smad signaling via an angiotensin II type I receptor interactionKidney International, 2004
- Role of Advanced Glycation End Products in Diabetic NephropathyJournal of the American Society of Nephrology, 2003
- The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetesThe FASEB Journal, 2003
- A Breaker of Advanced Glycation End Products Attenuates Diabetes-Induced Myocardial Structural ChangesCirculation Research, 2003
- The Mucosa of the Small IntestineClinical Pharmacokinetics, 2002
- Chelating Activity of Advanced Glycation End-product InhibitorsPublished by Elsevier BV ,2001
- End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensionsAmerican Journal of Kidney Diseases, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Sequential renal biopsies in insulin-dependent diabetic patients: Structural factors associated with clinical progressionKidney International, 1995
- Estimating glomerular number in situ using magnetic resonance imaging and biopsyKidney International, 1994